Skip to main content
Top
Published in: AIDS and Behavior 3/2019

01-03-2019 | Care | Original Paper

Data-Driven Goals for Curbing the U.S. HIV Epidemic by 2030

Authors: Heather Bradley, Eli S. Rosenberg, David R. Holtgrave

Published in: AIDS and Behavior | Issue 3/2019

Login to get access

Abstract

Progress in reducing HIV infections has been suboptimal despite availability of effective prevention and treatment interventions and national strategies to bring them to scale. As part of a community-driven process, we expanded previous epidemiologic models using updated surveillance data from the Centers for Disease Control and Prevention to estimate quantitative parameters for ambitious but attainable national HIV prevention goals. We estimated new HIV infections could be reduced by up to 67% and prevalence could begin to decline by 2030 if 95% targets for diagnosis, care retention, and viral suppression are met by 2025 and an additional 20% of transmissions are averted through targeted interventions such as pre-exposure prophylaxis. Notably, this would require the percentage of diagnosed persons retained in HIV care to increase by more than 35 percentage points, which would necessitate innovative models and a substantial expansion of supportive services. Although the HIV incidence reduction goal of 90% as unveiled in the 2019 State of the Union Address is likely unachievable with the current intervention toolkit, it is possible to begin to substantially reduce HIV prevalence in the next decade with sufficient investments and innovation.
Literature
1.
go back to reference Centers for Disease Control and Prevention. HIV Surveill. Report. 2017;2018:29. Centers for Disease Control and Prevention. HIV Surveill. Report. 2017;2018:29.
2.
go back to reference Singh S, Song R, Johnson AS, McCray E, Hall HI. HIV incidence, prevalence, and undiagnosed infections in U.S. men who have sex with men. Ann Intern Med. 2018;168(10):685–94.CrossRefPubMed Singh S, Song R, Johnson AS, McCray E, Hall HI. HIV incidence, prevalence, and undiagnosed infections in U.S. men who have sex with men. Ann Intern Med. 2018;168(10):685–94.CrossRefPubMed
3.
go back to reference Shah M, Perry A, Risher K, et al. Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. Lancet HIV. 2016;3(3):e140–6.CrossRefPubMedPubMedCentral Shah M, Perry A, Risher K, et al. Effect of the US National HIV/AIDS Strategy targets for improved HIV care engagement: a modelling study. Lancet HIV. 2016;3(3):e140–6.CrossRefPubMedPubMedCentral
4.
go back to reference Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations 2014. Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations 2014.
5.
go back to reference Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–47.CrossRefPubMed Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–47.CrossRefPubMed
7.
go back to reference Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.CrossRefPubMed Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.CrossRefPubMed
8.
go back to reference Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
9.
go back to reference Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
10.
go back to reference Gause NK, Brown JL, Welge J, Northern N. Meta-analyses of HIV prevention interventions targeting improved partner communication: effects on partner communication and condom use frequency outcomes. J Behav Med. 2018;41(4):423–40.CrossRefPubMed Gause NK, Brown JL, Welge J, Northern N. Meta-analyses of HIV prevention interventions targeting improved partner communication: effects on partner communication and condom use frequency outcomes. J Behav Med. 2018;41(4):423–40.CrossRefPubMed
11.
go back to reference Hergenrather KC, Emmanuel D, Durant S, Rhodes SD. Enhancing HIV prevention among young men who have sex with men: a systematic review of HIV behavioral interventions for young gay and bisexual men. AIDS Educ Prev. 2016;28(3):252–71.CrossRefPubMed Hergenrather KC, Emmanuel D, Durant S, Rhodes SD. Enhancing HIV prevention among young men who have sex with men: a systematic review of HIV behavioral interventions for young gay and bisexual men. AIDS Educ Prev. 2016;28(3):252–71.CrossRefPubMed
12.
go back to reference Laisaar KT, Raag M, Rosenthal M, Uuskula A. Behavioral interventions to reduce sexual risk behavior in adults with HIV/AIDS receiving HIV care: a systematic review. AIDS Patient Care STDS. 2015;29(5):288–98.CrossRefPubMedPubMedCentral Laisaar KT, Raag M, Rosenthal M, Uuskula A. Behavioral interventions to reduce sexual risk behavior in adults with HIV/AIDS receiving HIV care: a systematic review. AIDS Patient Care STDS. 2015;29(5):288–98.CrossRefPubMedPubMedCentral
13.
go back to reference Perez A, Santamaria EK, Operario D. A systematic review of behavioral interventions to reduce condomless sex and increase HIV testing for Latino MSM. J Immigr Minor Health. 2018;20(5):1261–76.CrossRefPubMedPubMedCentral Perez A, Santamaria EK, Operario D. A systematic review of behavioral interventions to reduce condomless sex and increase HIV testing for Latino MSM. J Immigr Minor Health. 2018;20(5):1261–76.CrossRefPubMedPubMedCentral
14.
go back to reference Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337–44.CrossRefPubMed Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337–44.CrossRefPubMed
15.
go back to reference Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545–63.CrossRefPubMed Platt L, Minozzi S, Reed J, et al. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545–63.CrossRefPubMed
16.
go back to reference White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States 2010. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States 2010.
17.
go back to reference White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020 2015. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States: updated to 2020 2015.
18.
go back to reference Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland 2014. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-track: ending the AIDS epidemic by 2030. Geneva, Switzerland 2014.
21.
go back to reference Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2015. 2018. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 20102015. 2018.
23.
go back to reference Bonacci RA, Holtgrave DRUSHIV. Incidence and transmission goals, 2020 and 2025. Am J Prev Med. 2017;53(3):275–81.CrossRefPubMed Bonacci RA, Holtgrave DRUSHIV. Incidence and transmission goals, 2020 and 2025. Am J Prev Med. 2017;53(3):275–81.CrossRefPubMed
24.
go back to reference Hall HI, Green TA, Wolitski RJ, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271–6.CrossRefPubMed Hall HI, Green TA, Wolitski RJ, et al. Estimated future HIV prevalence, incidence, and potential infections averted in the United States: a multiple scenario analysis. J Acquir Immune Defic Syndr. 2010;55(2):271–6.CrossRefPubMed
25.
go back to reference Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed
26.
go back to reference Jenness SM, Goodreau SM, Rosenberg E, et al. Impact of the centers for disease control’s HIV preexposure prophylaxis guidelines for men who have sex with men in the United States. J Infect Dis. 2016;214(12):1800–7.CrossRefPubMedPubMedCentral Jenness SM, Goodreau SM, Rosenberg E, et al. Impact of the centers for disease control’s HIV preexposure prophylaxis guidelines for men who have sex with men in the United States. J Infect Dis. 2016;214(12):1800–7.CrossRefPubMedPubMedCentral
27.
go back to reference Sullivan PS, Giler RM, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28(12):833–40.CrossRefPubMedPubMedCentral Sullivan PS, Giler RM, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28(12):833–40.CrossRefPubMedPubMedCentral
28.
go back to reference Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850–7.CrossRefPubMed Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850–7.CrossRefPubMed
29.
go back to reference Bonacci RA, Holtgrave DR. Simplified estimates of HIV incidence and transmission rates for the USA, 2008-2012. AIDS. 2016;30(2):332–3.CrossRefPubMed Bonacci RA, Holtgrave DR. Simplified estimates of HIV incidence and transmission rates for the USA, 2008-2012. AIDS. 2016;30(2):332–3.CrossRefPubMed
30.
go back to reference Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas, 2016. HIV Surveill Suppl Rep. 2018;23(4):1065–72. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas, 2016. HIV Surveill Suppl Rep. 2018;23(4):1065–72.
31.
go back to reference Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.CrossRefPubMedPubMedCentral Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.CrossRefPubMedPubMedCentral
33.
go back to reference Craw J, Gardner L, Rossman A, et al. Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model. BMC Health Serv Res. 2010;10:246.CrossRefPubMedPubMedCentral Craw J, Gardner L, Rossman A, et al. Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model. BMC Health Serv Res. 2010;10:246.CrossRefPubMedPubMedCentral
34.
go back to reference Higa DH, Crepaz N, Mullins MM, Prevention Research Synthesis Project. Identifying best practices for increasing linkage to, retention, and re-engagement in HIV medical care: findings from a systematic review, 1996–2014. AIDS Behav. 2015;24:951–66. Higa DH, Crepaz N, Mullins MM, Prevention Research Synthesis Project. Identifying best practices for increasing linkage to, retention, and re-engagement in HIV medical care: findings from a systematic review, 1996–2014. AIDS Behav. 2015;24:951–66.
35.
go back to reference Mizuno Y, Higa DH, Leighton CA, Roland KB, Deluca JB, Koenig LJ. Is HIV patient navigation associated with HIV care continuum outcomes? AIDS. 2018;32(17):2557–71.PubMed Mizuno Y, Higa DH, Leighton CA, Roland KB, Deluca JB, Koenig LJ. Is HIV patient navigation associated with HIV care continuum outcomes? AIDS. 2018;32(17):2557–71.PubMed
36.
go back to reference Jain KM, Maulsby C, Kinsky S, Charles V, Holtgrave DR, Team PCI. 2015–2020 national HIV/AIDS strategy goals for HIV linkage and retention in care: recommendations from program implementers. Am J Public Health. 2016;106(3):399–401.CrossRefPubMedPubMedCentral Jain KM, Maulsby C, Kinsky S, Charles V, Holtgrave DR, Team PCI. 2015–2020 national HIV/AIDS strategy goals for HIV linkage and retention in care: recommendations from program implementers. Am J Public Health. 2016;106(3):399–401.CrossRefPubMedPubMedCentral
37.
go back to reference Maulsby C, Sacamano P, Jain KM, et al. Barriers and facilitators to the implementation of a national HIV linkage, re-engagement, and retention in care program. AIDS Educ Prev. 2017;29(5):443–56.CrossRefPubMedPubMedCentral Maulsby C, Sacamano P, Jain KM, et al. Barriers and facilitators to the implementation of a national HIV linkage, re-engagement, and retention in care program. AIDS Educ Prev. 2017;29(5):443–56.CrossRefPubMedPubMedCentral
38.
go back to reference Tucker JD, Tso LS, Hall B, et al. Enhancing public health HIV interventions: a qualitative meta-synthesis and systematic review of studies to improve linkage to care, adherence, and retention. EBioMedicine. 2017;17:163–71.CrossRefPubMedPubMedCentral Tucker JD, Tso LS, Hall B, et al. Enhancing public health HIV interventions: a qualitative meta-synthesis and systematic review of studies to improve linkage to care, adherence, and retention. EBioMedicine. 2017;17:163–71.CrossRefPubMedPubMedCentral
39.
go back to reference Bradley H, Viall AH, Wortley PM, Dempsey A, Hauck H, Skarbinski J. Ryan white HIV/AIDS program assistance and HIV treatment outcomes. Clin Infect Dis. 2016;62(1):90–8.CrossRefPubMed Bradley H, Viall AH, Wortley PM, Dempsey A, Hauck H, Skarbinski J. Ryan white HIV/AIDS program assistance and HIV treatment outcomes. Clin Infect Dis. 2016;62(1):90–8.CrossRefPubMed
40.
go back to reference Weiser J, Beer L, Frazier EL, et al. Service delivery and patient outcomes in Ryan White HIV/AIDS program-funded and -nonfunded health care facilities in the United States. JAMA Intern Med. 2015;175(10):1650–9.CrossRefPubMedPubMedCentral Weiser J, Beer L, Frazier EL, et al. Service delivery and patient outcomes in Ryan White HIV/AIDS program-funded and -nonfunded health care facilities in the United States. JAMA Intern Med. 2015;175(10):1650–9.CrossRefPubMedPubMedCentral
41.
go back to reference AIDS United. Ending the HIV epidemic in the United States: a roadmap for federal action 2018. AIDS United. Ending the HIV epidemic in the United States: a roadmap for federal action 2018.
Metadata
Title
Data-Driven Goals for Curbing the U.S. HIV Epidemic by 2030
Authors
Heather Bradley
Eli S. Rosenberg
David R. Holtgrave
Publication date
01-03-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-019-02442-7

Other articles of this Issue 3/2019

AIDS and Behavior 3/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.